Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.
2.

Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Valera E, Masliah E.

Pharmacol Ther. 2013 Jun;138(3):311-22. doi: 10.1016/j.pharmthera.2013.01.013. Epub 2013 Feb 4. Review.

3.

Suppression of extensive neurofilament phosphorylation rescues α-Internexin/peripherin-overexpressing PC12 cells from neuronal cell death.

Lee WC, Kan D, Chen YY, Han SK, Lu KS, Chien CL.

PLoS One. 2012;7(8):e43883. doi: 10.1371/journal.pone.0043883. Epub 2012 Aug 27.

4.

A neuronal death model: overexpression of neuronal intermediate filament protein peripherin in PC12 cells.

Lee WC, Chen YY, Kan D, Chien CL.

J Biomed Sci. 2012 Jan 17;19:8. doi: 10.1186/1423-0127-19-8.

5.

The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies.

Brunden KR, Yao Y, Potuzak JS, Ferrer NI, Ballatore C, James MJ, Hogan AM, Trojanowski JQ, Smith AB 3rd, Lee VM.

Pharmacol Res. 2011 Apr;63(4):341-51. doi: 10.1016/j.phrs.2010.12.002. Epub 2010 Dec 14.

6.

MSC p43 required for axonal development in motor neurons.

Zhu X, Liu Y, Yin Y, Shao A, Zhang B, Kim S, Zhou J.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15944-9. doi: 10.1073/pnas.0901872106. Epub 2009 Aug 26.

7.

Neurofilament tail phosphorylation: identity of the RT-97 phosphoepitope and regulation in neurons by cross-talk among proline-directed kinases.

Veeranna, Lee JH, Pareek TK, Jaffee H, Boland B, Vinod KY, Amin N, Kulkarni AB, Pant HC, Nixon RA.

J Neurochem. 2008 Oct;107(1):35-49. doi: 10.1111/j.1471-4159.2008.05547.x. Epub 2008 Jul 4.

8.

Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease.

Deng Y, Li B, Liu F, Iqbal K, Grundke-Iqbal I, Brandt R, Gong CX.

FASEB J. 2008 Jan;22(1):138-45. Epub 2007 Aug 8.

9.

Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease.

Cairns NJ, Grossman M, Arnold SE, Burn DJ, Jaros E, Perry RH, Duyckaerts C, Stankoff B, Pillon B, Skullerud K, Cruz-Sanchez FF, Bigio EH, Mackenzie IR, Gearing M, Juncos JL, Glass JD, Yokoo H, Nakazato Y, Mosaheb S, Thorpe JR, Uryu K, Lee VM, Trojanowski JQ.

Neurology. 2004 Oct 26;63(8):1376-84.

10.

alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases.

Cairns NJ, Uryu K, Bigio EH, Mackenzie IR, Gearing M, Duyckaerts C, Yokoo H, Nakazato Y, Jaros E, Perry RH, Arnold SE, Lee VM, Trojanowski JQ.

Acta Neuropathol. 2004 Sep;108(3):213-23. Epub 2004 May 28.

11.

A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene.

Mersiyanova IV, Perepelov AV, Polyakov AV, Sitnikov VF, Dadali EL, Oparin RB, Petrin AN, Evgrafov OV.

Am J Hum Genet. 2000 Jul;67(1):37-46. Epub 2000 Jun 7.

12.
13.
14.
15.
16.
18.

Alzheimer's disease--neuropathological aspects.

Bergeron C.

Can J Vet Res. 1990 Jan;54(1):58-64. Review.

19.
20.

Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies.

Schmidt ML, Murray J, Lee VM, Hill WD, Wertkin A, Trojanowski JQ.

Am J Pathol. 1991 Jul;139(1):53-65.

Supplemental Content

Support Center